This study was conducted in people without COVID-19 and was designed to evaluate plasma ACE2 activity in healthy controls in comparison with patients with cardiovascular risk factors and/or disease, and the potential impact of plasma ACE2 activity levels on global coagulation assay parameters. This evidence concerns the gene ACE2 and COVID-19.